Top Markets
Coin of the day
Adagio Therapeutics, Inc. Adagio Therapeutics, Inc.

Adagio Therapeutics, Inc.

ADGI
株式のランク #16435
Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily... Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily focused on the discovery, development, and subsequent commercialization of antibody-based therapeutics designed to combat infectious diseases across the United States. Its most advanced product candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical trials. This antibody is being evaluated for both the treatment and prevention of coronavirus disease. Adagio Therapeutics also engages in strategic collaborations. It partners with Adimab, LLC to facilitate the discovery and optimization of novel proprietary antibodies. Furthermore, the company works with the Scripps Research Institute on research initiatives aimed at identifying vaccine candidates that could prevent, diagnose, or treat influenza and beta coronaviruses. Founded in 2020, Adagio Therapeutics maintains its headquarters in Waltham, Massachusetts.
株価
$4.64
最終同期: 2022-09-12
時価総額
$293.43M
変化(1日)
0.87%
変化(1年)
0.00%
US
取引 Adagio Therapeutics, Inc. (ADGI)

カテゴリー

Adagio Therapeutics, Inc.(ADGI)の株価履歴
終値の最高値: $4.63 (2022-09-01)

終値の最安値: $27.68 (2021-08-01)
Adagio Therapeutics, Inc. の株価履歴(2021 ~ 2026)
年間株価パフォーマンス
パフォーマンス
2022 -78.16%
2021 0.00%
類似企業または競合の株価
企業 株価 変化率 1年%
$548.15 36.70%
US
$1.03K 45.33%
NL
$153.87 536.09%
US
$121.61 -10.47%
AU
$748.60 6.90%
CH